Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1695131 | 0.86 | KMT2A (0.45) | ALDH1A1KDM4EHPGDNPSR1MAPT | |
| SCHEMBL819329 | 0.82 | L3MBTL1 (0.50) | ALDH1A1KDM4EHPGDNPSR1MAPT | |
| SCHEMBL15936293 | 0.81 | ALDH1A1 (0.58) | ALDH1A1KDM4EHPGDNPSR1MAPT | |
| SCHEMBL5364915 | 0.81 | ALDH1A1 (0.58) | ALDH1A1KDM4EHPGDNPSR1MAPT | |
| SCHEMBL5315678 | 0.81 | KDM4E (0.58) | ALDH1A1KDM4EHPGDNPSR1MAPT | |
| SCHEMBL27636776 | 0.81 | HPGD (0.49) | ALDH1A1KDM4EHPGDNPSR1MAPT | |
| SCHEMBL1539120 | 0.81 | ALDH1A1 (0.66) | ALDH1A1KDM4EHPGDNPSR1MAPT | |
| SCHEMBL4168214 | 0.81 | ALDH1A1 (0.47) | ALDH1A1KDM4EHPGDMAPTMEN1 | |
| SCHEMBL14499346 | 0.80 | KDM4E (0.56) | ALDH1A1KDM4EHPGDNPSR1MAPT | |
| SCHEMBL10120354 | 0.80 | KDM4E (0.56) | ALDH1A1KDM4EHPGDNPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724430-A1 | CONDENSED AZINES AS INHIBITORS OF CYCLIC ADP RIBOSE HYDROLASE | Flagship Pioneering Innovations VI, LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-3860636-B1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | DISC MEDICINE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| WO-2024254396-A1 | CONDENSED AZINES AS INHIBITORS OF CYCLIC ADP RIBOSE HYDROLASE | FLAGSHIP PIONEERING INNOVATIONS, VI, LLC (US) | 2024-12-12 | — | — | WO | disclosed |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240317733-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-09-26 | — | — | US | disclosed |
| US-20240207224-A1 | MACROCYCLIC CHALCONE-AMIDE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2024-06-27 | — | — | US | disclosed |
| WO-2024107783-A2 | NOVEL MACROCYCLIC CHALCONE-AMIDE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024107783-A2 | NOVEL MACROCYCLIC CHALCONE-AMIDE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-4292662-A2 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | Vanderbilt University (US) | 2023-12-20 | — | — | EP | disclosed |
| EP-1169302-B1 | N-(2-PHENYL-4-AMINO-BUTYL)-1-NAPHTHAMIDES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2004-09-29 | — | — | EP | disclosed |
| US-20040106610-A1 | Compounds | BERNSTEIN PETER ROBERT (US) | 2004-06-03 | — | — | US | disclosed |
| US-6586432-B2 | Peptide neurotransmitter suppressors such as N-((-2-(3,4-dichlorophenyl)-4-morholino)butyl)-N-methyl-2-methoxy-3-cyano-1 -naphthamide, used for prophylaxis of arthritis, pain, alzheimer's disease, schizophrenia, edema, rhinitis or asthma | ASTRAZENELA AB (SE) | 2003-07-01 | — | — | US | disclosed |
| US-20030092713-A1 | Neurokinin-1 receptor antagonists | BERNSTEIN PETER ROBERT (US) | 2003-05-15 | — | — | US | disclosed |
| US-6476077-B1 | N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists | ASTRAZENECA AB (SE) | 2002-11-05 | — | — | US | disclosed |
| US-6365602-B1 | FOR THERAPY OF DEPRESSION, ANXIETY, ASTHMA, PAIN, INFLAMMATION, URINARY INCONTINENCE AND OTHER DISEASE CONDITIONS | ASTRA ZENECA AB (SE) | 2002-04-02 | — | — | US | disclosed |
| EP-1169302-A1 | N-(2-PHENYL-4-AMINO-BUTYL)-1-NAPHTHAMIDES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2002-01-09 | — | — | EP | disclosed |
| EP-1097137-A1 | N-SUBSTITUTED NAPHTHALENE CARBOXAMIDES AS NEUROKININ-RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2001-05-09 | — | — | EP | disclosed |
| WO-2000059873-A1 | N-(2-PHENYL-4-AMINO-BUTYL)-1-NAPHTHAMIDES AS NEUROKININ-1 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000002859-A1 | N-SUBSTITUTED NAPHTHALENE CARBOXAMIDES AS NEUROKININ-RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106610-A1 | Compounds | NR2C2, NR0B2, NR5A2 | ALDH1A1 2538/4885KDM4E 2462/4885HPGD 3657/4885 |
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | MMP7, MATR3, SPINT2 | ALDH1A1 3877/4885KDM4E 1948/4885HPGD 1516/4885 |
| US-20240207224-A1 | MACROCYCLIC CHALCONE-AMIDE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, SARS1 | ALDH1A1 3183/4885KDM4E 1425/4885HPGD 1819/4885 |
| US-20240317733-A1 | CYCLOPROPANAMINE COMPOUND AND USE THEREOF | KDM1A, KDM1B, KDM2A | ALDH1A1 1643/4885KDM4E 13/4885HPGD 3049/4885 |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | ALDH1A1 2556/4885KDM4E 1156/4885HPGD 3190/4885 |
| US-20030092713-A1 | Neurokinin-1 receptor antagonists | NTSR2, NTSR1, CRHR2 | ALDH1A1 2644/4885KDM4E 2703/4885HPGD 3608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.